medcelerator · clinician one-pager
New Infusion Treatment for Thyroid Eye Disease
Lumvoa (veligrotug-vvze) for thyroid eye disease (active and chronic)
FDA Approved · United States · September 7, 2026
Condition: Thyroid Eye Disease
Who this is for
Lumvoa (veligrotug) is an infusion for thyroid eye disease, whether the disease is active or long-standing. The United States approved it on 26 June 2026. Treatment is five infusions over 12 weeks.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761530Orig1s000lbl.pdf
Possible routes (not confirmed)
United States · Not yet recruiting clinical trial · Applicability unknown
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
Trial not yet recruiting (ClinicalTrials.gov status: not yet taking patients).
https://clinicaltrials.gov/study/NCT07832136
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/lumvoa-veligrotug